Literature DB >> 25632993

The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients.

Kristen E Metzger1, Yvonne Rucker2, Mary Callaghan2, Michelle Churchill2, Borko D Jovanovic3, Teresa R Zembower1, Maureen K Bolon1.   

Abstract

OBJECTIVE: To evaluate the impact and burden of the new National Healthcare Safety Network surveillance definition, mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI), in hematology, oncology, and stem cell transplant populations.
DESIGN: Retrospective cohort study.
SETTING: Two hematology, oncology, and stem cell transplant units at a large academic medical center.
METHODS: Central line-associated bloodstream infections (CLABSIs) identified during a 14-month period were reviewed and classified as MBI-LCBI or non-MBI-LCBI (MBI-LCBI criteria not met). During this period, interventions to improve central line maintenance were implemented. Characteristics of patients with MBI-LCBI and non-MBI-LCBI were compared. Total CLABSI, MBI-LCBI, and non-MBI-LCBI rates were compared between baseline and postintervention phases of the study period.
RESULTS: Among 66 total CLABSI cases, 47 (71%) met MBI-LCBI criteria. Patients with MBI-LCBI and non-MBI-LCBI were similar in regard to most clinical and demographic characteristics. Between the baseline and postintervention study periods, the overall CLABSI rate decreased from 3.37 to 3.21 infections per 1,000 line-days (incidence rate ratio, 0.95; 4.7% reduction, P=.84), the MBI-LCBI rate increased from 2.08 to 2.61 infections per 1,000 line-days (incidence rate ratio, 1.25; 25.3% increase, P=.44), and the non-MBI-LCBI rate decreased from 1.29 to 0.60 infections per 1,000 line-days (incidence rate ratio, 0.47; 53.3% reduction, P=.12).
CONCLUSIONS: Most CLABSIs identified among hematology, oncology, and stem cell transplant patients met MBI-LCBI criteria, and CLABSI prevention efforts did not reduce these infections. Further review of the MBI-LCBI definition and impact is necessary to direct future definition changes and reporting mandates.

Entities:  

Mesh:

Year:  2015        PMID: 25632993     DOI: 10.1017/ice.2014.38

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  13 in total

1.  Bloodstream Infections: The peak of the iceberg.

Authors:  Claudio Viscoli
Journal:  Virulence       Date:  2016-02-18       Impact factor: 5.882

2.  Microbiology of Bloodstream Infections in Children After Hematopoietic Stem Cell Transplantation: A Single-Center Experience Over Two Decades (1997-2017).

Authors:  Sarah M Heston; Rebecca R Young; Hwanhee Hong; Ibukunoluwa C Akinboyo; John S Tanaka; Paul L Martin; Richard Vinesett; Kirsten Jenkins; Lauren E McGill; Kevin C Hazen; Patrick C Seed; Matthew S Kelly
Journal:  Open Forum Infect Dis       Date:  2020-09-30       Impact factor: 3.835

3.  The Centers for Disease Control and Prevention definition of mucosal barrier injury-associated bloodstream infection improves accurate detection of preventable bacteremia rates at a pediatric cancer center in a low- to middle-income country.

Authors:  Dara Torres; Miriam L González; Adriana Loera; Marco Aguilera; George Relyea; Paula Aristizabal; Miguela A Caniza
Journal:  Am J Infect Control       Date:  2016-01-05       Impact factor: 2.918

Review 4.  Bloodstream infections in neutropenic cancer patients: A practical update.

Authors:  Giulia Gustinetti; Malgorzata Mikulska
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

5.  Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation.

Authors:  Christopher E Dandoy; David Haslam; Adam Lane; Sonata Jodele; Kathy Demmel; Javier El-Bietar; Laura Flesch; Kasiani C Myers; Abigail Pate; Seth Rotz; Paulina Daniels; Gregory Wallace; Adam Nelson; Heather Waters; Beverly Connelly; Stella M Davies
Journal:  Biol Blood Marrow Transplant       Date:  2016-06-13       Impact factor: 5.742

Review 6.  Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis.

Authors:  C E Dandoy; M I Ardura; G A Papanicolaou; J J Auletta
Journal:  Bone Marrow Transplant       Date:  2017-03-27       Impact factor: 5.174

Review 7.  Surveillance of bloodstream infections in pediatric cancer centers - what have we learned and how do we move on?

Authors:  Arne Simon; Rhoikos Furtwängler; Norbert Graf; Hans Jürgen Laws; Sebastian Voigt; Brar Piening; Christine Geffers; Philipp Agyeman; Roland A Ammann
Journal:  GMS Hyg Infect Control       Date:  2016-05-12

8.  Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.

Authors:  Christopher E Dandoy; Soyoung Kim; Min Chen; Kwang Woo Ahn; Monica I Ardura; Valerie Brown; Saurabh Chhabra; Miguel Angel Diaz; Christopher Dvorak; Nosha Farhadfar; Aron Flagg; Siddartha Ganguly; Gregory A Hale; Shahrukh K Hashmi; Peiman Hematti; Rodrigo Martino; Taiga Nishihori; Roomi Nusrat; Richard F Olsson; Seth J Rotz; Anthony D Sung; Miguel-Angel Perales; Caroline A Lindemans; Krishna V Komanduri; Marcie L Riches
Journal:  JAMA Netw Open       Date:  2020-01-03

9.  Incidence, risk factors and healthcare costs of central line-associated nosocomial bloodstream infections in hematologic and oncologic patients.

Authors:  Claas Baier; Lena Linke; Matthias Eder; Frank Schwab; Iris Freya Chaberny; Ralf-Peter Vonberg; Ella Ebadi
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

10. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.